Session 2: Oral Abstract Session

Chair(s)

• 

  Michael Staehler, MD, PhD

  Ludwig-Maximilians University of Munich, Germany

Presentations:

• 09:15 – 09:25 CEST

  Abstract 1: Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: results from a discontinued study arm of CheckMate 9ER
  

  Presenter: Bernard Escudier, MD – Institut Gustave-Roussy
• 09:25 – 09:35 CEST

  Abstract 2: Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey
  

  Presenter: Cristiane Decat Bergerot, PhD – Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa
• 09:35 – 09:45 CEST

  Abstract 3: A systematic review of heterogeneity in outcome reporting, definition and measurement in localised kidney cancer
  

  Presenter: Katharina Beyer, MSc – Translational Oncology and Urology Research (TOUR), King’s College London, London, UK
• 09:45 – 09:55 CEST

  Abstract 4: ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)
  

  Presenter: Will Ince, FRCR MRCP MRCGP MB BS – Addenbooke's Hospital
• 09:55 – 10:10 CEST

  Panel Question and Answer